rss
Br J Ophthalmol 92:120-125 doi:10.1136/bjo.2007.125179
  • Original Article
    • Laboratory science

Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE2 release, and cytokine expression in a model of acute ocular inflammation

Open Access
  1. R Cruz1,
  2. J D Quintana-Hau2,
  3. J R González2,
  4. R Tornero-Montaño2,
  5. L M Baiza-Durán2,
  6. L Vega1
  1. 1
    Sección Externa de Toxicología, CINVESTAV, San Pedro Zacatenco, Mexico
  2. 2
    Dirección Científica, Laboratorios Sophia SA de CV, Jalisco, Mexico
  1. L Vega, Sección Externa de Toxicología, CINVESTAV, Av. IPN 2508, San Pedro Zacatenco, Mexico DF, 07360, Mexico; lvega{at}cinvestav.mx
  • Accepted 29 June 2007
  • Published Online First 25 October 2007

Abstract

Aim: To determine the efficacy of meloxicam ophthalmic formulation on COX-2 activity and expression, inflammation-related cytokines expression and inflammation in an ocular inflammation model.

Methods: Ocular inflammation was induced in New Zealand rabbits by topical application of croton oil (3%) for 3 h. An ophthalmic solution of 0.03% meloxicam, 0.1% sodium diclofenac or vehicle (Sophisen™) was administered every 4 h. Conjunctiva, cornea, aqueous humour and vitreous humour were collected.

Results: In irritated eyes, 72 h of meloxicam treatment downregulated COX-2 expression and activity (mRNA by RT-PCR and PGE2 levels by ELISA, respectively) in a time-dependent manner and reduced inflammation. Meanwhile, diclofenac failed to reduce COX-2 mRNA or PGE2 to basal levels after 7 days of treatment. Meloxicam treatment downregulated IL-6 and IFN-γ expression in the conjunctiva and IL-1β and TNF-α expression in the cornea. Diclofenac failed to modify these cytokines in both tissues. Meloxicam treatment increased the expression of IL-6 in conjunctiva, and IL-10 in cornea, while diclofenac had no effect on these cytokines.

Conclusion: Meloxicam treatment was more efficient than diclofenac in downregulating the expression and activity of COX-2, reducing inflammation, and modifying the inflammatory-related cytokines.

Footnotes

  • Funding: This project was financed by Laboratorios SOPHIA SA de CV, Mexico.

  • Competing interests: None declared.

Open Access

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article